Network pharmacology and molecular docking analyses on Scutellaria barbata indicate that JUN and RELA are potential targets to treat and prevent COVID-19 viremia

The coronavirus disease 2019 (COVID-19) pandemic has been ongoing for more than two years and is likely to continue. Scutellaria barbata (S. barbata) is a traditional Chinese herbal medicine with anti-inflammatory and anti-viral properties and has demonstrated therapeutic effects on patients with COVID-19. Our study aims to shed light on the underlying mechanism and identify possible therapeutic targets. The data on the expression of COVID-19 viremia-associated genes were retrieved from five disease-gene databases. The expression pattern of genes encoding for functional monomer components of S. barbata was retrieved from the Traditional Chinese Medicine Systems Pharmacology platform. To determine the potential mechanism, we used “Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses,” and the protein-protein interaction (PPI) network was constructed using the STRING online tool. CytoNCA, a plug-in for Cytoscape, was used for screening the hub genes. The AutoDocktools and the “PyMOL” software were used for performing molecular docking between active molecules of drugs and disease-target proteins. We identified the S. barbata target and COVID-19 viremia-associated gene sets consisting of 42 genes. GO functional enrichment analysis showed that S. barbata can act by the regulation of cytokine activity and the cytokine-mediated signaling pathway. KEGG pathway enrichment analysis showed that these genes were enriched in several pathways like T helper cell 17 differentiation, the Tumor necrosis factor, and Interleukin-17 signaling pathways. In addition, we identified 17 hub genes, including JUN, RELA, TNF, IL6, etc., using the PPI network and subnetworks. Molecular docking was performed on two highly significant genes: JUN and RELA. The former is a transcription factor, regulating activation-induced cell death, Interferon response post-COVID-19 infection, CD95 ligand promoter activity, and the expression of cytokine genes in T-cells. The five active compounds of S. barbata, including baicalein, wogonin, quercetin, luteolin, and beta-sitosterol, could enter the active pockets of COVID-19 to exert potential therapeutic effects on COVID-19 viremia. JUN and RELA could weaken T cell-mediated immune and cytokine-related inflammatory responses. They could be used as therapeutic targets and could aid in reducing COVID-19 viremia.

Scutellaria barbata; COVID-19; Viremia; Signaling pathway; Network pharmacology; Molecular docking

[1] Chen Q, Rahman K, Wang SJ, Zhou S, Zhang H. Scutellaria barbata: a review on chemical constituents, pharmacological activities and clinical applications. Current Pharmaceutical Design. 2020; 26: 160–175.

[2] Na LI, Ping W, Tie-Feng S, Li H, Ya-Nan HU, Hai-Tao DU, et al. Research progress on chemical constituents, pharmacological action and quality control of Scutellaria barbata. Zhongguo Zhong Yao Za Zhi. 2020; 45: 5117–5128.

[3] Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet. 2020; 395: 470–473.

[4] Ciotti M, Ciccozzi M, Pieri M, Bernardini S. The COVID-19 pandemic: viral variants and vaccine efficacy. Critical Reviews in Clinical Laboratory Sciences. 2022; 59: 66–75.

[5] Burki TK. Coronavirus in China. The Lancet Respiratory Medicine. 2020; 8: 238.

[6] Araf Y, Akter F, Tang YD, Fatemi R, Parvez SA, Zheng C, et al. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. Journal of Medical Virology. 2022; 94: 1825–1832.

[7] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020; 395: 1033–1034.

[8] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395: 497–506.

[9] Shang Y, Pan C, Yang X, Zhong M, Shang X, Wu Z, et al. Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. Annals of Intensive Care. 2020; 10: 73.

[10] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. AMA. 2020; 324: 782–793.

[11] Huang K, Zhang P, Zhang Z, Youn JY, Wang C, Zhang HC, et al. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. Pharmacology & Therapeutics. 2021; 225: 107843.

[12] Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of Cheminformatics. 2014; 6: 13.

[13] The UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Research. 2021; 49: D480–D489.

[14] Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The Genecards Suite: from gene data mining to disease genome sequence analyses. Current Protocols in Bioinformatics. 2016; 54: 1.30.1–1.30.33.

[15] Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Research. 2015; 43: D789–D798.

[16] Brown GR, Hem V, Katz KS, Ovetsky M, Wallin C, Ermolaeva O, et al. Gene: a gene-centered information resource at NCBI. Nucleic Acids Research. 2015; 43: D36–D42.

[17] Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Research. 2017; 45: D353–D361.

[18] Piñero J, Ramirez-Anguita JM, Sauch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Research. 2020; 48: D845–D855.

[19] The Gene Ontology Consortium. The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Research. 2019; 47: D330–D338.

[20] Wu J, Mao X, Cai T, Luo J, Wei L. KOBAS server: a web-based platform for automated annotation and pathway identification. Nucleic Acids Research. 2006; 34: W720–W724.

[21] Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: network analysis and visualization of proteomics data. Journal of Proteome Research. 2019; 18: 623–632.

[22] Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Research. 2021; 49: D605–D612.

[23] Tang Y, Li M, Wang J, Pan Y, Wu F. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems. 2015; 127: 67–72.

[24] Rose Y, Duarte JM, Lowe R, Segura J, Bi C, Bhikadiya C, et al. RCSB protein data bank: architectural advances towards integrated searching and efficient access to macromolecular structure data from the PDB archive. Journal of Molecular Biology. 2021; 433: 166704.

[25] Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Research. 2016; 44: D1202–D1213.

[26] O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open babel: an open chemical toolbox. Journal of Cheminformatics. 2011; 3: 33.

[27] Mooers BHM. Shortcuts for faster image creation in PyMOL. Protein Science. 2020; 29: 268–276.

[28] Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. Journal of Computer-Aided Molecular Design. 2010; 24: 417–422.

[29] Ferreira LG, Dos SR, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015; 20: 13384–13421.

[30] Hsin KY, Ghosh S, Kitano H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PLoS One. 2013; 8: e0083922.

[31] Lin TJ, Yin SY, Hsiao PW, Yang NS, Wang IJ. Transcriptomic analysis reveals a controlling mechanism for NLRP3 and IL-17A in dextran sulfate sodium (DSS)-induced colitis. Scientific Reports. 2018; 8: 14927.

[32] Feng W, Zhong X, Zheng X, Liu Q, Liu M, Liu X, et al. Study on the effect and mechanism of quercetin in treating gout arthritis. International Immunopharmacology. 2022; 111: 109112.

[33] Ji Z, Donaldson IJ, Liu J, Hayes A, Zeef LAH, Sharrocks AD. The forkhead transcription factor FOXK2 promotes AP-1-mediated transcriptional regulation. Molecular and Cellular Biology. 2012; 32: 385–398.

[34] Atsaves V, Leventaki V, Rassidakis GZ, Claret FX. AP-1 transcription factors as regulators of immune responses in cancer. Cancers. 2019; 11: 1037.

[35] Baumann S, Hess J, Eichhorst ST, Krueger A, Angel P, Krammer PH, et al. An unexpected role for FosB in activation-induced cell death of T cells. Oncogene. 2003; 22: 1333–1339.

[36] Abd El-Lateef AE, Ismail MM, Thabet G, Cabrido N. Complete blood cells count abnormalities in COVID-19 patients and their prognostic significance: single center study in Makkah, Saudi Arabia. Saudi Medical Journal. 2022; 43: 572–578.

[37] Lo PE, Dieli F, Meraviglia S. Lymphopenia in COVID-19: γδ T Cells-based therapeutic opportunities. Vaccines. 2021; 9: 562.

[38] Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102: 5138–5143.

[39] Yin X, Riva L, Pu Y, Martin-Sancho L, Kanamune J, Yamamoto Y, et al. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Reports. 2021; 34: 108628.

[40] Spinelli G, Biddeci G, Artale A, Valentino F, Tarantino G, Gallo G, et al. A new p65 isoform that bind the glucocorticoid hormone and is expressed in inflammation liver diseases and COVID-19. Scientific Reports. 2021; 11: 22913.

[41] Gałgańska H, Gałgański A. Mitogen-activated protein kinases are carbon dioxide receptors in plants. bioRχiv. 2020. [Preprint].

[42] Galganska H, Jarmuszkiewicz W, Galganski L. Carbon dioxide inhibits COVID-19-type proinflammatory responses through extracellular signal-regulated kinases 1 and 2, novel carbon dioxide sensors. Cellular and Molecular Life Sciences. 2021; 78: 8229–8242.

[43] Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Reviews in Medical Virology. 2020; 30: 1–9.

[44] McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019; 50: 892–906.

[45] Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nature Reviews Drug Discovery. 2012; 11: 763–776.

[46] Zemke AC, Robinson KM. Right on the nose: IL-17C and nasal host defense. American Journal of Respiratory Cell and Molecular Biology. 2020; 62: 10–11.

[47] Rathore JS, Wang Y. Protective role of Th17 cells in pulmonary infection. Vaccine. 2016; 34: 1504–1514.

[48] Shibabaw T. Inflammatory cytokine: IL-17A signaling pathway in patients present with COVID-19 and current treatment strategy. Journal of Inflammation Research. 2020; 13: 673–680.

[49] Li M, Guo W, Dong Y, Wang X, Dai D, Liu X, et al. Elevated exhaustion levels of NK and CD8(+) T cells as indicators for progression and prognosis of COVID-19 disease. Frontiers in Immunology. 2020; 11: 580237.

[50] Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. The Journal of Clinical Investigation. 2020; 130: 6409–6416.

[51] Ablamunits V, Lepsy C. Blocking TNF signaling may save lives in COVID-19 infection. Molecular Biology Reports. 2022; 49: 2303–2309.